Compare Gilead Sciences, Inc. (GILD) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Norfolk Southern Corporation — how do they compare? Gilead Sciences, Inc. trades at $132.95 (market cap $163.51B), while Norfolk Southern Corporation trades at $336.45 (market cap $73.79B). The key difference: Gilead Sciences, Inc. is far larger — about 2.2× Norfolk Southern Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NSC | |
|---|---|---|
Market Cap | $163.51B | $73.79B |
Sector | Health | Technology |
52-Week High | $155.80 | $328.54 |
52-Week Low | $108.22 | $260.32 |
Enterprise Value | $178.05B | $89.55B |
Dividend Yield | 2.49% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Norfolk Southern (NSC) trades at $335, up 2.5% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI indicates overbought conditions near resistance at $335. Fundamentally, NSC demonstrates robust profitability with 21.9% net margins and consistent earnings beats, though valuation multiples remain elevated. Recent news focuses on the proposed Union Pacific merger, with regulatory scrutiny ongoing.
Outlook remains cautiously optimistic with analyst consensus at $344.40 (2.8% upside). Key opportunities include merger synergies and solid cash flow generation, while risks involve regulatory hurdles for the merger and rich valuations limiting near-term upside. Earnings on July 23 will be critical for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
